WINTON GROUP Ltd Purchases Shares of 18,516 Moderna, Inc. (NASDAQ:MRNA)

WINTON GROUP Ltd acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,516 shares of the company’s stock, valued at approximately $770,000.

A number of other hedge funds have also modified their holdings of MRNA. State Street Corp raised its holdings in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after buying an additional 178,115 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after acquiring an additional 19,819 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Moderna by 9.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company’s stock worth $97,472,000 after acquiring an additional 211,426 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MRNA. Leerink Partners decreased their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Barclays downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Citigroup started coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price target for the company. Evercore ISI set a $50.00 price objective on shares of Moderna in a research note on Friday, February 14th. Finally, The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and cut their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $59.00.

Moderna Trading Down 3.1 %

Shares of MRNA stock opened at $31.12 on Friday. The stock has a 50 day simple moving average of $34.72 and a 200 day simple moving average of $44.38. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The stock has a market cap of $12.03 billion, a P/E ratio of -3.35 and a beta of 1.86.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.